Hikma shares slide after cutting guidance for year
Jordan -based Hikma Pharmaceuticals (LSE: HIK) was 4% lower as Thursday’s London trading neared its end while markets digested its third-quarter trading update.
The company’s share price had risen from Tuesday’s £1,663.90 to close at £1,763 on Wednesday as it benefitted from the widespread pharma stock boost following the US elections results, but it was down at £1,688 again as Thursday’s trading entered its last hour.
Overall, Hikma announcing that it was generating good revenue growth and expected revenue for the full year to grow by approximately 35%. However, the new $2 billion estimate in constant currency is slightly down on previous guidance of between $2 billion to $2.1 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze